Alvotech
NASDAQALVO short interest fell 20.3% over one week to 4.76M shares as of Sept 16, with utilization at 88% and availability at 73%, signaling moderating short pressure in the biosimilar name.
ALVO reports today with the stock up 15% in a month but still sitting below where every major bull on the Street wants it — a gap the print will either start to close or widen further. The borrow market tells a nuanced…
ALVO enters its August 20 earnings report in an unusual position: the stock has rallied 14% in a month, a bellwether analyst just initiated coverage with a bullish call, and yet short sellers built positions…
Snapshot as of 20 Sept 2026
ALVO walks into its May 7 earnings report carrying the strongest earnings-surprise track record in its universe — yet a stock price still down 85% from where most analysts pegged fair value two years ago. The standout…
Alvotech enters the post-earnings tape with a Q1 revenue miss that landed after the close on May 6 — $105.9M against a $140.8M consensus — and a stock already under pressure heading in. The miss is the story this week.…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALVO — free to start on ORTEX.
Sign up for free →Open ALVO on ORTEX